Question Everything!Everything!! |
Welcome to Truth, FREEDOM OR ANARCHY,Campaign of Conscience. , is an alternative media and news site that is dedicated to the truth, true journalism and the truth movement. The articles, ideas, quotes, books and movies are here to let everyone know the truth about our universe. The truth will set us free, it will enlighten, inspire, awaken and unite us. Armed with the truth united we stand, for peace, freedom, health and happiness for all
Question Everything!
This blog does not promote
This blog does not promote, support, condone, encourage, advocate, nor in any way endorse any racist (or "racialist") ideologies, nor any armed and/or violent revolutionary, seditionist and/or terrorist activities. Any racial separatist or militant groups listed here are solely for reference and Opinions of multiple authors including Freedom or Anarchy Campaign of conscience.
Tuesday, July 28, 2015
Big Pharma’s Profiteers: You Want Us to Pay What for These Meds?
Big Pharma’s Profiteers: You Want Us to Pay What for These Meds?
It is no secret that the pill profit party is over for drug companies. Bestselling pills like Lipitor, Seroquel, Zyprexa, Singular, Concerta, Cymbalta and Abilify have gone off patent and Wall Street is moving on to industries that offer better returns.
To combat investor disenchantment, drug companies have rolled out expensive drugs that treat such rare conditions, they almost sound like satire. If you are sleepy during the day, you may have narcolepsy says Jazz Pharmaceuticals which its drug Xyrem treats for $35,000 per year. If you have frequent diarrhea, gas and bloating, you may have exocrine pancreatic insufficiency says AbbVie to sell the drug Creon.
Drug makers are even not above scaring the populace if it sells drugs for rare diseases. Your back pain may not be from working out at all but from a disease called ankylosing spondylitis, says AbbVie, a condition that can be treated with its biologic drug Humira for as much as $20,000 a year. (Injectable “biologic” drugs are a new drug industry push because they are so expensive and less susceptible to generic competition than pills.)
The drug industry is also trying to stay a Wall Street darling with new, uber priced drugs—notably hepatitis C drugs. Gilead Sciences sold $12.4 billion worth of Sovaldi at $1000 a pill last year, reports the New York Times “straining the budgets of insurance companies and Medicaid programs.”
http://www.nytimes.com/2015/07/25/business/us-approves-drug-that-can-sharply-lower-cholesterol-levels.html?_r=0
While drug company representatives initially tried to cast the outrageous prices as recouping their research and development costs they quickly back pedaled into admitting the drugs are priced on “value”—what they are “worth” for the patient’s health. Needless to say such valuations come pretty close to the definition of extortion—or offers you “can’t refuse.”
Even business writers cry foul. Why does the same hepatitis C drug that costs $84,000 a year in the US cost $900 a year in Egypt asked Forbes staff writer Avik Roy. Since most hepatitis C patients in the US are uninsured, underinsured or imprisoned, taxpayers pick up the bill through Medicaid, the VA and prison systems writes Roy.
Now Sanofi and Regeneron Pharmaceuticals are rolling out a cholesterol lowering drug which could be embraced by the millions who made the statin Lipitor the best selling drug in the world before it went off patent. Yet the list price of Praluent, an injectable biologic, is over $14,600 a year. Like Gilead, Sanofi and Regeneron say the price reflects what it is worth in potential benefits to patients and savings to the health care system—e.g. what they can get.
Nor is cost the only question with the new cholesterol drug. Increasingly, high bad cholesterol is viewed as a weak cardiovascular risk factor versus other factors like inflammation. Cholesterol lowering drugs can also be used to duck important lifestyle changes. “Plenty of adults down statins regularly and shine off healthy eating because they know a cheeseburger and steak can’t fool a statin,” writes Dr. Michael J. Breus on the Huffington Post.
http://www.huffingtonpost.com/martha-rosenberg/statins_b_1818370.html
Luckily, lawmakers are demanding cost breakdowns from drug companies on the new four-digit priced drugs. How much are true costs and what is profiteering? Some states are drafting bills that would allow insurers to refuse to pay for a drug if the manufacturer did not file the required cost breakdown reports.
What is the response of drug makers to bills addressing expensive drugs? They would be costly to comply with, they say.
By Martha Rosenberg
Martha Rosenberg is an investigative health reporter. She is the author of Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).
Pro Deo et Constitutione – Libertas aut Mors
Semper Vigilans Fortis Paratus et Fidelis
Joseph F Barber- http://josephfreedomoranarchy.blogspot.com/
It is no secret that the pill profit party is over for drug companies. Bestselling pills like Lipitor, Seroquel, Zyprexa, Singular, Concerta, Cymbalta and Abilify have gone off patent and Wall Street is moving on to industries that offer better returns.
To combat investor disenchantment, drug companies have rolled out expensive drugs that treat such rare conditions, they almost sound like satire. If you are sleepy during the day, you may have narcolepsy says Jazz Pharmaceuticals which its drug Xyrem treats for $35,000 per year. If you have frequent diarrhea, gas and bloating, you may have exocrine pancreatic insufficiency says AbbVie to sell the drug Creon.
Drug makers are even not above scaring the populace if it sells drugs for rare diseases. Your back pain may not be from working out at all but from a disease called ankylosing spondylitis, says AbbVie, a condition that can be treated with its biologic drug Humira for as much as $20,000 a year. (Injectable “biologic” drugs are a new drug industry push because they are so expensive and less susceptible to generic competition than pills.)
The drug industry is also trying to stay a Wall Street darling with new, uber priced drugs—notably hepatitis C drugs. Gilead Sciences sold $12.4 billion worth of Sovaldi at $1000 a pill last year, reports the New York Times “straining the budgets of insurance companies and Medicaid programs.”
http://www.nytimes.com/2015/07/25/business/us-approves-drug-that-can-sharply-lower-cholesterol-levels.html?_r=0
While drug company representatives initially tried to cast the outrageous prices as recouping their research and development costs they quickly back pedaled into admitting the drugs are priced on “value”—what they are “worth” for the patient’s health. Needless to say such valuations come pretty close to the definition of extortion—or offers you “can’t refuse.”
Even business writers cry foul. Why does the same hepatitis C drug that costs $84,000 a year in the US cost $900 a year in Egypt asked Forbes staff writer Avik Roy. Since most hepatitis C patients in the US are uninsured, underinsured or imprisoned, taxpayers pick up the bill through Medicaid, the VA and prison systems writes Roy.
Now Sanofi and Regeneron Pharmaceuticals are rolling out a cholesterol lowering drug which could be embraced by the millions who made the statin Lipitor the best selling drug in the world before it went off patent. Yet the list price of Praluent, an injectable biologic, is over $14,600 a year. Like Gilead, Sanofi and Regeneron say the price reflects what it is worth in potential benefits to patients and savings to the health care system—e.g. what they can get.
Nor is cost the only question with the new cholesterol drug. Increasingly, high bad cholesterol is viewed as a weak cardiovascular risk factor versus other factors like inflammation. Cholesterol lowering drugs can also be used to duck important lifestyle changes. “Plenty of adults down statins regularly and shine off healthy eating because they know a cheeseburger and steak can’t fool a statin,” writes Dr. Michael J. Breus on the Huffington Post.
http://www.huffingtonpost.com/martha-rosenberg/statins_b_1818370.html
Luckily, lawmakers are demanding cost breakdowns from drug companies on the new four-digit priced drugs. How much are true costs and what is profiteering? Some states are drafting bills that would allow insurers to refuse to pay for a drug if the manufacturer did not file the required cost breakdown reports.
What is the response of drug makers to bills addressing expensive drugs? They would be costly to comply with, they say.
By Martha Rosenberg
Martha Rosenberg is an investigative health reporter. She is the author of Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).
Pro Deo et Constitutione – Libertas aut Mors
Semper Vigilans Fortis Paratus et Fidelis
Joseph F Barber- http://josephfreedomoranarchy.blogspot.com/
LAWFUL REBELLIONSTAND FOR WHAT IS RIGHT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Anyone is welcome to use their voice here at FREEDOM OR ANARCHY,Campaign of Conscience.THERE IS NO JUSTICE IN AMERICA FOR THOSE WITH OUT MONEY if you seek real change and the truth the first best way is to use the power of the human voice and unite the world in a common cause our own survival I believe that to meet the challenges of our times, human beings will have to develop a greater sense of universal responsibility. Each of us must learn to work not just for oneself, ones own family or ones nation, but for the benefit of all humankind. Universal responsibility is the key to human survival. It is the best foundation for world peace,“Never be afraid to raise your voice for honesty and truth and compassion against injustice and lying and greed. If people all over the world...would do this, it would change the earth.” Love and Peace to you all stand free and your ground feed another if you can let us the free call it LAWFUL REBELLION standing for what is right